Avanos Medical, Inc. Q3 2024 Results

Avanos Medical, Inc. (NYSE: AVNS) reported its third-quarter results on October 30, 2024. The company announced sales of approximately $170 million and adjusted diluted earnings per share (EPS) of $0.36. Despite not meeting its organic growth target, Avanos completed the divestiture of its respiratory health business, leading to positive cash flow and a strong balance sheet. Interim CEO Michael Greiner, who succeeded Joe Woody following his retirement, emphasized the company’s commitment to strategic transformation and improving operational profitability.

Key Takeaways

• Q3 sales: $170 million and adjusted EPS of $0.36.
• Divestiture of respiratory health plans completed.
• Q3 positive cash flow: $20 million; Q4 expected to be $30 million.
• Expected Q4 revenue: $175 million to $180 million.
• FDA approved the CORGRIP SR Nasal Bridle System.
• Long-term growth expected from new product launches in pain management recovery and improvements.
• Pursuing strategic M&A and share repurchases, focusing on transformation.

Company Outlook

• Projected Q4 revenue: $175 million to $180 million with a 59% adjusted gross margin.
• Estimated net debt by year-end: $20 million; leverage ratio below 0.25.
• More growth projections for FY '25 to be shared at the upcoming JPMorgan conference.
• Continued focus on strategic transformation to meet financial goals.

Performance Highlights

Bearish

• Underperformance in the surgical pain portfolio, affecting organic growth targets.
• Inconsistent top-line results led to adjustments in go-to-market strategies.

Bullish

• Growth in enteral feeding and over 30% growth in the surgical pain business (Ambit).
• Stable revenue growth for Game Ready, with expectations for maintenance in Q4 and 2025.

Misses

• Did not meet mid-single-digit organic growth target.

Q&A Highlights

• Revenue growth uncertainty for ON-Q due to past supply constraints.
• Testing new direct-to-consumer strategies for Game Ready and improving the rental model.
• Key focus on executing the transformation plan initiated 15 months ago, with managed divestitures and acquisitions.

Avanos Medical's third-quarter performance highlights its transition under new leadership, emphasizing strategic realignment and operational improvements. Stakeholders can await more detailed projections for 2025 at the upcoming JPMorgan conference in January.

InvestingPro Insights

Avanos Medical's financial performance and strategic initiatives resonate with InvestingPro insights, such as aggressive share buybacks indicating management confidence. The current Price to Book ratio of 0.66 suggests potential undervaluation, enhanced by the company’s strong balance sheet and positive cash flow.

Full Earnings Call Transcript Highlights

Operator: Good morning, and welcome to Avanos Medical's Third Quarter 2024 Earnings Call. The presenters will discuss operational and financial results, the current business environment, and transformation efforts.

Gary Blackford (Chair): Recent leadership changes have improved Avanos’s strategic positioning as a focused medical device company.

Michael Greiner (Interim CEO): We generated $170 million in sales and are working to optimize our portfolio. Delays in surgical pain impacts have affected our performance.

Overall, the call emphasized ongoing transformation efforts and strategic focus going forward, including updates on product launches and possible growth factors.

This article is AI-generated and edited for clarity.